Acambis Plc said its smallpox vaccine, ACAM2000, has been approved by the US Food and Drug Administration (FDA) for active immunisation of persons determined to be at high risk of smallpox infection.
Antisoma Plc has reported positive results from a Phase 2 trial of its cancer drug, ASA404, which is intended to treat non-small-cell lung cancer. Data from the trial will be disclosed at the World Lung Cancer Conference in Soeul, Korea on 5 September 2007.
Vivalis, a French company that has developed a stem cell technology for the manufacture of vaccines, said it has licensed-in platform technology from North Carolina State University for producing undifferentiated avian cell cultures using avian primordial germ cells.
TheraGenetics Ltd, a spinout from the Institute of Psychiatry at King's College in London in April 2006, hopes to have its gene-based diagnostic tests ready in about two years, its chief executive, Richard Kivel, said.
Shares of GPC Biotech AG have begun to recover after the company announced that it was withdrawing its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for accelerated approval of its cancer-drug candidate, satraplatin.
Kinaxo Biotechnologies GmbH has received a grant of about €1 million from Germany’s Ministry of Education and Research (BMBF) to develop a new way of quantifying small molecule-protein interactions by combining mass spectrometry with Kinaxo’s chemical proteomics technology platform, KinaTor.
Pharming Group NV said that it has made “important progress” in the process of developing and obtaining registration for its recombinant human C1 inhibitor, Rhucin.
Researchers at the Karolinska Institutet in Sweden have described the structure of a human membrane protein that is understood to have a major influence on the development of asthma.
The Medicon Valley Academy changed its name to Medicon Valley Alliance, effective 1 July 2007.
Intercytex Group Plc announced on 26 June, 2007 that its replacement for skin grafts was successful in a Phase I trial, representing the first time that laboratory-made, living human skin has been fully and consistently integrated into the human body.